Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02410824 · ClinicalTrials.gov registry record · NA
Bilateral Dispensing Clinical Trial of Stenfilcon A Against Etafilcon A for Astigmatism
A NA study, sponsored by CooperVision.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT02410824: Completed NA study, sponsored by CooperVision.
NCT02410824 is a NA study that has completed, run by CooperVision. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02410824, a NA study, has completed, sponsored by CooperVision.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
Bilateral dispensing clinical trial of stenfilcon A against etafilcon A for astigmatism.
Primary Outcome
Subjective ratings of lens performance for comfort assessed at baseline and 1 week. Comfort Scale 0-100, 0=extremely uncomfortable/cannot tolerate, 100=extremely comfortable/cannot be felt.
Interventions
- DEVICE stenfilcon A toric lens
- DEVICE etafilcon A toric lens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2015-04 |
| Est. Completion | 2015-06 |
| Phase | NA |
What the finished NCT02410824 record still lists
NCT02410824 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which stenfilcon A toric lens is the first listed.
NCT02410824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02410824 about?
NCT02410824 is a clinical study titled "Bilateral Dispensing Clinical Trial of Stenfilcon A Against Etafilcon A for Astigmatism". Bilateral dispensing clinical trial of stenfilcon A against etafilcon A for astigmatism.
What is the current status of trial NCT02410824?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2015-04. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02410824?
The interventions under investigation include: stenfilcon A toric lens (DEVICE), etafilcon A toric lens (DEVICE).
Who is sponsoring clinical trial NCT02410824?
This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02410824's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia